Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CPIX's Cash to Debt is ranked higher than
87% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.62 vs. CPIX: No Debt )
CPIX' s 10-Year Cash to Debt Range
Min: 1.16   Max: No Debt
Current: No Debt

Equity to Asset 0.87
CPIX's Equity to Asset is ranked higher than
92% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. CPIX: 0.87 )
CPIX' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.91
Current: 0.87

0.42
0.91
F-Score: 4
Z-Score: 5.20
M-Score: -2.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -11.87
CPIX's Operating margin (%) is ranked higher than
53% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. CPIX: -11.87 )
CPIX' s 10-Year Operating margin (%) Range
Min: -11.87   Max: 23.96
Current: -11.87

-11.87
23.96
Net-margin (%) -6.57
CPIX's Net-margin (%) is ranked higher than
53% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. CPIX: -6.57 )
CPIX' s 10-Year Net-margin (%) Range
Min: -6.57   Max: 24.72
Current: -6.57

-6.57
24.72
ROE (%) -2.65
CPIX's ROE (%) is ranked higher than
55% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. CPIX: -2.65 )
CPIX' s 10-Year ROE (%) Range
Min: -2.65   Max: 39.58
Current: -2.65

-2.65
39.58
ROA (%) -2.40
CPIX's ROA (%) is ranked higher than
55% of the 748 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. CPIX: -2.40 )
CPIX' s 10-Year ROA (%) Range
Min: -2.4   Max: 19.21
Current: -2.4

-2.4
19.21
ROC (Joel Greenblatt) (%) -53.34
CPIX's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. CPIX: -53.34 )
CPIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -53.34   Max: 1685.65
Current: -53.34

-53.34
1685.65
Revenue Growth (%) -7.10
CPIX's Revenue Growth (%) is ranked higher than
52% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. CPIX: -7.10 )
CPIX' s 10-Year Revenue Growth (%) Range
Min: -7.1   Max: 47.5
Current: -7.1

-7.1
47.5
» CPIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CPIX Guru Trades in Q2 2013

John Rogers 1,425,705 sh (+165.48%)
Jim Simons 250,868 sh (+3.55%)
» More
Q3 2013

CPIX Guru Trades in Q3 2013

John Rogers 1,758,955 sh (+23.37%)
Jim Simons 177,662 sh (-29.18%)
» More
Q4 2013

CPIX Guru Trades in Q4 2013

John Rogers 2,538,760 sh (+44.33%)
Jim Simons 133,400 sh (-24.91%)
» More
Q1 2014

CPIX Guru Trades in Q1 2014

John Rogers 2,663,520 sh (+4.91%)
Jim Simons 95,597 sh (-28.34%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.00
CPIX's P/B is ranked higher than
94% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. CPIX: 1.00 )
CPIX' s 10-Year P/B Range
Min: 0.9   Max: 4.84
Current: 1

0.9
4.84
P/S 2.70
CPIX's P/S is ranked higher than
73% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. CPIX: 2.70 )
CPIX' s 10-Year P/S Range
Min: 1.65   Max: 6.82
Current: 2.7

1.65
6.82
EV-to-EBIT -5.79
CPIX's EV-to-EBIT is ranked lower than
57% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.81 vs. CPIX: -5.79 )
CPIX' s 10-Year EV-to-EBIT Range
Min: 1.3   Max: 43.2
Current: -5.79

1.3
43.2
PEG 14.50
CPIX's PEG is ranked higher than
74% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 367.50 vs. CPIX: 14.50 )
CPIX' s 10-Year PEG Range
Min: 1.63   Max: 39.99
Current: 14.5

1.63
39.99
Shiller P/E 25.60
CPIX's Shiller P/E is ranked higher than
88% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPIX: 25.60 )
CPIX' s 10-Year Shiller P/E Range
Min: 16.26   Max: 35.82
Current: 25.6

16.26
35.82
Current Ratio 6.10
CPIX's Current Ratio is ranked higher than
89% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. CPIX: 6.10 )
CPIX' s 10-Year Current Ratio Range
Min: 1.45   Max: 14.46
Current: 6.1

1.45
14.46
Quick Ratio 5.45
CPIX's Quick Ratio is ranked higher than
90% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. CPIX: 5.45 )
CPIX' s 10-Year Quick Ratio Range
Min: 1.38   Max: 13.46
Current: 5.45

1.38
13.46

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.00
CPIX's Price/Net Cash is ranked higher than
99% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPIX: 2.00 )
CPIX' s 10-Year Price/Net Cash Range
Min: 1.37   Max: 6.72
Current: 2

1.37
6.72
Price/Net Current Asset Value 1.70
CPIX's Price/Net Current Asset Value is ranked higher than
99% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPIX: 1.70 )
CPIX' s 10-Year Price/Net Current Asset Value Range
Min: 1.21   Max: 5.93
Current: 1.7

1.21
5.93
Price/Tangible Book 1.30
CPIX's Price/Tangible Book is ranked higher than
91% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. CPIX: 1.30 )
CPIX' s 10-Year Price/Tangible Book Range
Min: 1.04   Max: 5.21
Current: 1.3

1.04
5.21
Price/DCF (Projected) 1.00
CPIX's Price/DCF (Projected) is ranked higher than
96% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. CPIX: 1.00 )
CPIX' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 1.35
Current: 1

0.7
1.35
Price/Median PS Value 1.10
CPIX's Price/Median PS Value is ranked higher than
76% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. CPIX: 1.10 )
CPIX' s 10-Year Price/Median PS Value Range
Min: 0.65   Max: 2.48
Current: 1.1

0.65
2.48
Earnings Yield (Greenblatt) 9.20
CPIX's Earnings Yield (Greenblatt) is ranked higher than
87% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. CPIX: 9.20 )
CPIX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 76.6
Current: 9.2

2.3
76.6
Forward Rate of Return (Yacktman) 2.99
CPIX's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. CPIX: 2.99 )
CPIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.9   Max: 16.4
Current: 2.99

1.9
16.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:CBJ.Germany
Cumberland Pharmaceuticals Inc., was incorporated in Tennessee on January 6, 1999. It is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company's target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 65 sales representatives and managers as of March 1, 2013. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which they do business. It promotes Acetadote and Caldolor through its dedicated hospital sales team and currently utilize two distinct sales teams to address its primary target markets: a hospital sales force for the acute care market and a field sales force for the gastroenterology market. It competes with the product attributes such as efficacy, safety, ease-of-use and cost-effectiveness.
» More Articles for CPIX

Headlines

Articles On GuruFocus.com
Speculative Options Buys Apr 29 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 16 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
Cumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014 Jul 22 2014
Cumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014 Jul 22 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 02 2014
CUMBERLAND PHARMACEUTICALS INC Financials May 21 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition May 19 2014
Cumberland Pharmaceuticals' (CPIX) CEO A. J. Kazimi on Q1 2014 Results - Earnings Call Transcript May 13 2014
Cumberland Pharmaceuticals Reports First Quarter 2014 Financial Results May 13 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 12 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 09 2014
Cumberland Pharmaceuticals Launches Vaprisol® Promotion May 07 2014
Cumberland Pharmaceuticals And Gloria Pharmaceuticals Announce Joint Research & Development... May 06 2014
Cumberland Pharmaceuticals To Announce First Quarter 2014 Financial Results On May 13, 2014 Apr 29 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Apr 18 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 11 2014
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Mar 07 2014
Caldolor® Pediatric Pain Study Results To Be Presented At The Pediatric Anesthesiology 2014... Mar 07 2014
Caldolor® Pediatric Pain Study Results To Be Presented At The Pediatric Anesthesiology 2014... Mar 07 2014
Message From CEO Mar 05 2014
Cumberland Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript Mar 04 2014
Cumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results Mar 04 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide